A case series of live attenuated vaccine administration in dupilumab‐treated children with atopic dermatitis
Pediatric Dermatology · 2024
DOI: 10.1111/pde.15518 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Dermatology, 2024. Verfasst von Elaine C Siegfried und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Pediatrics, Saint Louis University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Mumps, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regeneron Pharmaceuticals Inc., Sanofi.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background and Objective Current regulatory labeling recommends avoiding live vaccine use in dupilumab‐treated patients. Clinical data are not available to support more specific guidance for live or live attenuated vaccines administration in dupilumab‐treated patients.
Methods
Children (6 months–5 years old) with moderate‐to‐severe atopic dermatitis (AD) enrolled in a phase 2/3 clinical trial of dupilumab (LIBERTY AD PRESCHOOL Part A/B; NCT03346434) and subsequently participated in the LIBERTY AD PED‐OLE (NCT02612454). During these studies, protocol deviations occurred in nine children who received measles, mumps, rubella (MMR) vaccine with or without varicella vaccine; five with a ≤12‐week gap between dupilumab administration and vaccination and four with a >12‐week gap after discontinuing dupilumab.
Results
Nine children (1 female; 8 male) had severe AD at baseline (8–56 months old). Of the nine children, five had a ≤12‐week gap ranged 1–7 weeks between dupilumab administration and vaccination who received MMR vaccine ( n = 2) or MMR and varicella vaccines ( n = 3); among these, one resumed dupilumab treatment as early as 2 days and four resumed treatment 18–43 days after vaccination. No treatment‐emergent adverse events, including serious adverse events and infections, were reported within the 4‐week post‐vaccination period in any children.
Conclusions
In this case series of dupilumab‐treated children with severe AD who received MMR vaccine with or without varicella vaccine, no adverse effects (including vaccine‐related infection) were reported within 4 weeks after vaccination. Further studies are warranted to evaluate the safety, tolerability, and immune response to live attenuated vaccines in dupilumab‐treated patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Pediatrics, Saint Louis University School of Medicine, St. Louis, Missouri, USA.
- Department of Pediatric Dermatology, Cardinal Glennon Children's Hospital, St. Louis, Missouri, USA.
- Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of Pediatrics, Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Sanofi, Cambridge, Massachusetts, USA.
- Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
ORCID-Profile: Elaine C Siegfried, Sonya L Cyr, Brad Shumel
Förderung
- Regeneron Pharmaceuticals Inc.
- Sanofi
Zitieren
APA
Siegfried, E. C., Wine Lee, L., Spergel, J. M., Prescilla, R., Uppal, S., Coleman, A., Bansal, A., Cyr, S. L., & Shumel, B. (2024). A case series of live attenuated vaccine administration in dupilumab‐treated children with atopic dermatitis. Pediatric Dermatology. https://doi.org/10.1111/pde.15518
Vancouver
Siegfried EC, Wine Lee L, Spergel JM, Prescilla R, Uppal S, Coleman A, et al. A case series of live attenuated vaccine administration in dupilumab‐treated children with atopic dermatitis. Pediatric Dermatology. 2024. doi:10.1111/pde.15518
BibTeX
@article{Siegfried2024,
author = {Siegfried, Elaine C and Wine Lee, Lara and Spergel, Jonathan M and Prescilla, Randy and Uppal, Sumeet and Coleman, Anna and Bansal, Ashish and Cyr, Sonya L and Shumel, Brad},
title = {A case series of live attenuated vaccine administration in dupilumab‐treated children with atopic dermatitis},
journal = {Pediatric Dermatology},
year = {2024},
doi = {10.1111/pde.15518}
}
EUVIMED